• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    11/18/25 4:17:35 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    elmd20251107_8k.htm
    false 0001488917 0001488917 2025-11-14 2025-11-14
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549 
         
     
    FORM 8-K 
         
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): November 14, 2025
         
     
    ELECTROMED, INC.
    (Exact Name of Registrant as Specified in Its Charter)
     
    Minnesota
    001-34839
    41-1732920
    (State or Other Jurisdiction of
    Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification
    Number)
     
    500 Sixth Avenue NW
    New Prague, MN 56071
    (Address of Principal Executive Offices) (Zip Code)
     
    (952) 758-9299
    (Registrant’s Telephone Number, Including Area Code)
     
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
         
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Common Stock, $0.01 par value
     
    ELMD
     
    NYSE American LLC
    (Title of each class)
     
    (Trading Symbol)
     
    (Name of each exchange on which registered)
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.07
    Submission of Matters to a Vote of Security Holders.
     
    At the annual meeting of shareholders of Electromed, Inc. (the “Company”) held on November 14, 2025, the following proposals, each as described in further detail in the definitive proxy statement filed on September 30, 2025, were voted upon by our shareholders as set forth below:
     
    1.
    The following individuals designated by our Board as nominees for director were elected for a one-year term or until a successor has been elected and qualified, thereby setting the number of directors at eight, with voting as follows:
     
    Name
    For
    Withheld
    Broker Non-Votes
    James L. Cunniff
    5,022,691
    20,061
    1,416,368
    Stan K. Erickson
    4,958,039
    84,713 1,416,368
    Gregory J. Fluet
    4,686,278
    356,474
    1,416,368
    Joseph L. Galatowitsch
    4,969,344
    73,408
    1,416,368
    Kathleen S. Skarvan
    5,007,992
    34,760
    1,416,368
    Andrew J. Summers
    4,967,176
    75,576
    1,416,368
    Kathleen A. Tune
    4,964,920
    77,832
    1,416,368
    Andrea M. Walsh
    4,965,887
    76,865
    1,416,368
     
     
    2.
    Our shareholders ratified the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2026, with voting as follows:
     
       
    For
    Against
    Abstain
     
       
    6,435,180
    5,610
    18,330
     
     
    3.
    Our shareholders approved, on a non-binding and advisory basis, our executive compensation, with voting as follows:
     
     
    For
    Against
    Abstain
    Broker Non-Votes
     
    4,713,558
    309,673
    19,521
    1,416,368
     
     
    4.
    Our shareholders recommended, on a non-binding and advisory basis, that votes on named executive officer compensation should occur every year, with voting as follows:
     
     
    1 Year
    2 Years
    3 Years
    Abstain
    Broker Non-Votes
     
    4,783,259
    6,533
    237,314
    15,646
    1,416,368
     
     
    Based on the voting results, our Board of Directors has determined to continue to include a shareholder vote to approve executive compensation in its proxy materials on an annual basis.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    ELECTROMED, INC.
         
    Date: November 18, 2025
    By:
    /s/ Bradley M. Nagel
     
    Name:
    Bradley M. Nagel
     
    Title:
    Chief Financial Officer
     
     
     
    Get the next $ELMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Lake Street
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Electromed with a new price target

    Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00

    8/27/25 8:41:37 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tune Kathleen A was granted 3,000 shares, increasing direct ownership by 25% to 15,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:16:07 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Erickson Stan K. was granted 3,000 shares, increasing direct ownership by 8% to 38,817 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:12:20 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fluet Gregory was granted 3,000 shares, increasing direct ownership by 17% to 21,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:11:51 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces Share Repurchase Authorization

    Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that on September 9, 2025, its Board of Directors authorized Electromed to repurchase up to $10.0 million of Electromed common stock. This follows the exhaustion of Electromed's most recent share repurchase authorization in the fourth quarter of fiscal 2025, as previously reported. The timing and amount of share repurchases, if any, will be determined by management based on its evaluation of market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades

    9/9/25 9:00:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Electromed, Inc. (0001488917) (Filer)

    11/18/25 4:17:35 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Electromed Inc.

    10-Q - Electromed, Inc. (0001488917) (Filer)

    11/12/25 4:11:47 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Electromed, Inc. (0001488917) (Filer)

    11/12/25 4:07:57 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results

    Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY 2025 Company Highlights Net revenue increased 17.3% to a record $17.4 million in Q4 FY 2025, from $14.8 million in the fourth quarter of the prior fiscal year. Operating income was a record $3.0 million, a 30.2% increase from the fourth quarter of the prior fiscal year. Net income was $2.2 million, or $0.25 p

    8/26/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care